JP2023012463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023012463A5 JP2023012463A5 JP2022161464A JP2022161464A JP2023012463A5 JP 2023012463 A5 JP2023012463 A5 JP 2023012463A5 JP 2022161464 A JP2022161464 A JP 2022161464A JP 2022161464 A JP2022161464 A JP 2022161464A JP 2023012463 A5 JP2023012463 A5 JP 2023012463A5
- Authority
- JP
- Japan
- Prior art keywords
- pithindevirus
- segment
- utr
- segmented
- deviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 89
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 23
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 8
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 5
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 208000037581 Persistent Infection Diseases 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000001524 infective effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010077753 type II interferon receptor Proteins 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000017143 RNA Polymerase I Human genes 0.000 description 3
- 108010013845 RNA Polymerase I Proteins 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 240000005708 Eugenia stipitata Species 0.000 description 2
- 235000006149 Eugenia stipitata Nutrition 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000712910 Pichinde mammarenavirus Species 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024146333A JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338400P | 2016-05-18 | 2016-05-18 | |
| US62/338,400 | 2016-05-18 | ||
| JP2019513483A JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
| PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513483A Division JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146333A Division JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023012463A JP2023012463A (ja) | 2023-01-25 |
| JP2023012463A5 true JP2023012463A5 (https=) | 2023-04-11 |
| JP7547433B2 JP7547433B2 (ja) | 2024-09-09 |
Family
ID=58800799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513483A Active JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2022161464A Active JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513483A Active JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20190135875A1 (https=) |
| EP (1) | EP3458593A1 (https=) |
| JP (3) | JP7254018B2 (https=) |
| KR (2) | KR102671785B1 (https=) |
| CN (2) | CN117486979A (https=) |
| AU (2) | AU2017266738B2 (https=) |
| BR (1) | BR112018073794A2 (https=) |
| CA (1) | CA3023599A1 (https=) |
| EA (1) | EA201892648A1 (https=) |
| IL (2) | IL262963B2 (https=) |
| MX (2) | MX2018013956A (https=) |
| NZ (1) | NZ788311A (https=) |
| SG (1) | SG11201810048VA (https=) |
| WO (1) | WO2017198726A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| SI3218504T1 (sl) | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| CA3003557A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| DK3373959T3 (da) | 2015-11-12 | 2022-09-19 | Hookipa Biotech Gmbh | Arenaviruspartikler som cancervacciner |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| WO2021089853A1 (en) | 2019-11-07 | 2021-05-14 | Universität Basel | Arenaviruses as vectors |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| BR112022024404A2 (pt) | 2020-05-29 | 2023-02-07 | Hookipa Biotech Gmbh | Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| CN117280027A (zh) | 2021-03-23 | 2023-12-22 | 霍欧奇帕生物科技有限公司 | 用于治疗前列腺癌的沙粒病毒 |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CA3236106A1 (en) | 2021-11-08 | 2023-05-11 | Henning Lauterbach | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| EP2968506B1 (en) * | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
| CN107109371A (zh) * | 2014-09-22 | 2017-08-29 | 明尼苏达大学评议会 | 皮钦德病毒反向遗传学系统及其使用方法 |
-
2017
- 2017-05-17 IL IL262963A patent/IL262963B2/en unknown
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active Active
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 IL IL314272A patent/IL314272A/en unknown
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko active Pending
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt active IP Right Grant
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 NZ NZ788311A patent/NZ788311A/en unknown
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en not_active Ceased
-
2018
- 2018-11-14 MX MX2024005757A patent/MX2024005757A/es unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP7547433B2/ja active Active
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146333A patent/JP2024170461A/ja active Pending
-
2025
- 2025-06-06 US US19/230,758 patent/US20260109736A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023012463A5 (https=) | ||
| JP2019516410A5 (https=) | ||
| Bangari et al. | Development of nonhuman adenoviruses as vaccine vectors | |
| JP2017535267A5 (https=) | ||
| US6156497A (en) | Recombinase-mediated generation of adenoviral vectors | |
| US6403370B1 (en) | Oncolytic/immunogenic complementary-adenoviral vector system | |
| US20240018546A1 (en) | Single cycle replicating adenovirus vectors | |
| JP2023524915A (ja) | 腫瘍溶解性ウイルスワクチン及びそれと免疫細胞の併用による腫瘍治療薬物 | |
| Strayer | Gene therapy using SV40‐derived vectors: What does the future hold? | |
| JP2018536433A5 (https=) | ||
| WO1998035028A9 (en) | An oncolytic/immunogenic complementary-adenoviral vector system | |
| CN1132791A (zh) | 转染动物细胞的重组dna病毒载体 | |
| Polo et al. | Virus-based vectors for human vaccine applications | |
| AU753809B2 (en) | Recombinant adenoviral vectors comprising a splicing sequence | |
| JP2008539746A (ja) | ワクチン組成物 | |
| JP2007082562A (ja) | 医薬的および診断的使用のための組み換えフオーミーウイルスベクター、および組み換えフオーミーウイルスベクターの作製方法 | |
| JP5969044B2 (ja) | アデノウイルス生産新規細胞株及びその用途 | |
| CN1665921A (zh) | 用于免疫治疗的腺病毒载体 | |
| AU780822B2 (en) | Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors | |
| JP4951204B2 (ja) | 組換えアデノウイルスベクターとその応用 | |
| NZ748120A (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| Wilson | Adenoviruses as Vectors for Human Gene Therapy | |
| NZ748120B2 (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| AU3345801A (en) | Recombinase-mediated generation of adenoviral vectors |